AbbVie Inc (ABBV)vsElevai Labs, Inc. Common Stock (ELAB)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
ELAB
Elevai Labs, Inc. Common Stock
$2.53
-0.39%
HEALTHCARE · Cap: $11.08M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 10364597% more annual revenue ($61.16B vs $590,080). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ELAB
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Intrinsic value data unavailable for ELAB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ELAB
The strongest argument for ELAB centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ELAB
The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ELAB carries more volatility with a beta of 0.71 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 20/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Elevai Labs, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Elevai Labs, Inc. (Ticker: ELAB) is a cutting-edge technology company focused on revolutionizing artificial intelligence and machine learning applications. With its advanced data analytics platforms, Elevai Labs facilitates enhanced decision-making across key sectors, particularly in healthcare and finance, enabling organizations to extract actionable insights from complex datasets. Positioned at the forefront of the rapidly evolving tech landscape, the company is well-equipped to capitalize on emerging trends, thereby delivering significant value and operational efficiency to its clients and stakeholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?